BUDGET IMPACT OF ORAL NIRMATRELVIR/RITONAVIR IN PATIENTS AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19 IN THE US

被引：0
|
作者：
Sandin, R. [1 ]
Veenstra, D. [2 ]
Dzingina, M. [3 ]
Vankelegom, M. [4 ]
Sullivan, S. [2 ]
Campbell, D. [5 ]
Ma, C. [4 ]
Harrison, C. [4 ]
Draica, F. [6 ]
Wiemken, T. L. [6 ]
Mugwagwa, T. [6 ]
机构：
[1] Pfizer AB, Stockholm, Sweden
[2] Curta Inc, Seattle, WA USA
[3] Pfizer, London, England
[4] Hlth Econ & Outcomes Res Ltd, Cardiff, Wales
[5] Curta Inc, S Kingstown, RI USA
[6] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE644
引用
收藏
页码：S177 / S177
页数：1
相关论文
共 50 条
  • [31] The Efficacy and Safety of Nirmatrelvir/Ritonavir Against COVID-19 in Elderly Patients
    Xiang, Zheng
    Wang, Yueyuan
    Qu, Yuchen
    Lv, Bo
    Han, Junping
    Xu, Delai
    Fan, Kai
    Su, Cunjin
    Shen, Zhu
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2024, 17
  • [32] Prediction of COVID-19 Patients at High Risk of Progression to Severe Disease
    Dai, Zhenyu
    Zeng, Dong
    Cui, Dawei
    Wang, Dawei
    Feng, Yanling
    Shi, Yuhan
    Zhao, Liangping
    Xu, Jingjing
    Guo, Wenjuan
    Yang, Yuexiang
    Zhao, Xinguo
    Li, Duoduo
    Zheng, Ye
    Wang, Ao
    Wu, Minmin
    Song, Shu
    Lu, Hongzhou
    FRONTIERS IN PUBLIC HEALTH, 2020, 8
  • [33] Comparison of Azvudine and Nirmatrelvir/ Ritonavir and Combined Use in Patients with COVID-19
    Hu, Cheng-Yi
    Cui, Wen-Shuai
    Lei, Yi
    Tang, Yu-Wen
    Zhang, Yan-Yan
    Su, Qi-Min
    Peng, Fang
    Zeng, Yun-Fei
    Song, Jia-Lin
    Luo, Cheng-Na
    Zhou, Yan
    Li, Xin-Yan
    Zhao, Zhu-Xiang
    INFECTION AND DRUG RESISTANCE, 2023, 16 : 7797 - 7808
  • [34] Nirmatrelvir plus ritonavir remains effective in vaccinated patients at risk of progression with COVID-19: A systematic review and meta-analysis
    Li, Huamin
    Xiang, Huairong
    He, Bei
    Zhang, Qizhi
    Peng, Wenxing
    JOURNAL OF GLOBAL HEALTH, 2023, 13
  • [35] Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19
    Focosi, Daniele
    Nicastri, Emanuele
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (10)
  • [36] Safety of Nirmatrelvir/Ritonavir in Dialysis Patients with COVID-19 The End of the Beginning?
    Yilmam, Osman A. A.
    Leaf, David E. E.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (04): : 427 - 429
  • [37] Nirmatrelvir+ritonavir-related AEs in patients with COVID-19 infections
    Reactions Weekly, 2023, 1957 (1) : 11 - 11
  • [38] No emergence of resistance mutations in COVID-19 patients receiving nirmatrelvir/ritonavir
    Palomino-Cabrera, Rosalia
    Tejerina, Francisco
    Molero-Salinas, Andrea
    Veintimilla, Cristina
    Catalan, Pilar
    Ferris, Maria
    Osorio, Santiago
    Alonso, Roberto
    Munoz, Patricia
    de Viedma, Dario de Garcia
    Perez-Lago, Laura
    JOURNAL OF MEDICAL VIROLOGY, 2024, 96 (01)
  • [39] Predictors of nirmatrelvir-ritonavir receipt among COVID-19 patients in a large US health system
    Malden, Deborah E.
    Mclaughlin, John M.
    Hong, Vennis
    Lewnard, Joseph
    Ackerson, Bradley K.
    Puzniak, Laura
    Kim, Jeniffer S.
    Takhar, Harpreet
    Frankland, Timothy B.
    Slezak, Jeff M.
    Tartof, Sara Y.
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [40] Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in CKD Patients With COVID-19
    Cheng, Franco Wing Tak
    Yan, Vincent Ka Chun
    Wan, Eric Yuk Fai
    Chui, Celine Sze Ling
    Lai, Francisco Tsz Tsun
    Wong, Carlos King Ho
    Li, Xue
    Zhang, Irene Ran
    Tang, Sydney Chi Wai
    Wong, Ian Chi Kei
    Chan, Esther Wai Yin
    KIDNEY INTERNATIONAL REPORTS, 2024, 9 (05): : 1244 - 1253
12345